AUGMENT: Is the combination of lenalidomide & rituximab efficacious in elderly patients with iNHL?

L: English

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Marek Trněný, Charles University Hospital, Prague, CZ. We asked: AUGMENT trial: Is the combination of lenalidomide and rituximab efficacious in elderly patients with indolent non-Hodgkin lymphoma?

Marek Trněný gives an overview of the AUGMENT study design and results of the post-hoc analysis of the data in the elderly population. He concludes that the combination is safe and offers clinical benefit to older patients, especially those with follicular lymphoma.

Was this article informative? Thank you for your feedback!
50% of people found this article informative